Cargando…

Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure

New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely for patients to fully benefit. Gastric acid antisecretory drugs and particularly proton pum...

Descripción completa

Detalles Bibliográficos
Autores principales: Raoul, J.L., Moreau-Bachelard, C., Gilabert, M., Edeline, J., Frénel, J.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024146/
https://www.ncbi.nlm.nih.gov/pubmed/36764092
http://dx.doi.org/10.1016/j.esmoop.2023.100880
_version_ 1784909041362796544
author Raoul, J.L.
Moreau-Bachelard, C.
Gilabert, M.
Edeline, J.
Frénel, J.S.
author_facet Raoul, J.L.
Moreau-Bachelard, C.
Gilabert, M.
Edeline, J.
Frénel, J.S.
author_sort Raoul, J.L.
collection PubMed
description New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely for patients to fully benefit. Gastric acid antisecretory drugs and particularly proton pump inhibitors (PPIs) revolutionized the treatment of gastroduodenal ulcers and severe gastroesophageal reflux, but are frequently overused for symptomatic treatment of epigastric pain or heartburn. Long-term acid suppression may alter the efficacy of many anticancer drugs, such as tyrosine kinase inhibitors (TKIs), cyclin-dependent kinase (CDK) 4/6 inhibitors and immune checkpoint inhibitors (ICIs), by either decreasing gastric acid secretion and thus drug absorption, or by modifying the gut microbiome that modulates the response to ICIs. Oncologists thus need to pay particular attention to the concomitant use of PPIs and anticancer drugs. These interactions translate into major clinical impacts, with demonstrated loss of efficacy for some TKIs (erlotinib, gefitinib, pazopanib), and conflicting results with many other oral drugs, including capecitabine and CDK 4/6 inhibitors. Furthermore, the profound changes in the gut microbiome due to using PPIs have shown that the benefit of using ICIs may be suppressed in patients treated with PPIs. As the use of PPIs is not essential, we must apply the precautionary principle. The first sentence of a recent Comment in Nature was “Every day, millions of people are taking medications that will not help them”. We fear that every day millions of cancer patients are taking medications that harm them. While this may well be only association and not causation, there is enough to make us pause until we reach a clear answer. All these data should encourage medical oncologists to refrain from prescribing PPIs, explaining to patients the risks of interaction in order to prevent inappropriate prescription by another physician.
format Online
Article
Text
id pubmed-10024146
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100241462023-03-19 Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure Raoul, J.L. Moreau-Bachelard, C. Gilabert, M. Edeline, J. Frénel, J.S. ESMO Open Review New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely for patients to fully benefit. Gastric acid antisecretory drugs and particularly proton pump inhibitors (PPIs) revolutionized the treatment of gastroduodenal ulcers and severe gastroesophageal reflux, but are frequently overused for symptomatic treatment of epigastric pain or heartburn. Long-term acid suppression may alter the efficacy of many anticancer drugs, such as tyrosine kinase inhibitors (TKIs), cyclin-dependent kinase (CDK) 4/6 inhibitors and immune checkpoint inhibitors (ICIs), by either decreasing gastric acid secretion and thus drug absorption, or by modifying the gut microbiome that modulates the response to ICIs. Oncologists thus need to pay particular attention to the concomitant use of PPIs and anticancer drugs. These interactions translate into major clinical impacts, with demonstrated loss of efficacy for some TKIs (erlotinib, gefitinib, pazopanib), and conflicting results with many other oral drugs, including capecitabine and CDK 4/6 inhibitors. Furthermore, the profound changes in the gut microbiome due to using PPIs have shown that the benefit of using ICIs may be suppressed in patients treated with PPIs. As the use of PPIs is not essential, we must apply the precautionary principle. The first sentence of a recent Comment in Nature was “Every day, millions of people are taking medications that will not help them”. We fear that every day millions of cancer patients are taking medications that harm them. While this may well be only association and not causation, there is enough to make us pause until we reach a clear answer. All these data should encourage medical oncologists to refrain from prescribing PPIs, explaining to patients the risks of interaction in order to prevent inappropriate prescription by another physician. Elsevier 2023-02-08 /pmc/articles/PMC10024146/ /pubmed/36764092 http://dx.doi.org/10.1016/j.esmoop.2023.100880 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Raoul, J.L.
Moreau-Bachelard, C.
Gilabert, M.
Edeline, J.
Frénel, J.S.
Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
title Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
title_full Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
title_fullStr Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
title_full_unstemmed Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
title_short Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
title_sort drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024146/
https://www.ncbi.nlm.nih.gov/pubmed/36764092
http://dx.doi.org/10.1016/j.esmoop.2023.100880
work_keys_str_mv AT raouljl drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure
AT moreaubachelardc drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure
AT gilabertm drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure
AT edelinej drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure
AT freneljs drugdruginteractionswithprotonpumpinhibitorsincancerpatientsanunderrecognizedcauseoftreatmentfailure